36,215 Shares in Danaher Co. (NYSE:DHR) Purchased by Triavera Capital LLC

Triavera Capital LLC purchased a new stake in shares of Danaher Co. (NYSE:DHR - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 36,215 shares of the conglomerate's stock, valued at approximately $8,313,000. Danaher accounts for about 4.5% of Triavera Capital LLC's holdings, making the stock its 12th largest holding.

Other institutional investors also recently bought and sold shares of the company. Heck Capital Advisors LLC bought a new position in Danaher during the 4th quarter valued at about $27,000. Decker Retirement Planning Inc. purchased a new position in shares of Danaher during the fourth quarter valued at approximately $31,000. Golden State Wealth Management LLC bought a new position in shares of Danaher during the fourth quarter valued at approximately $31,000. Strategic Financial Concepts LLC purchased a new stake in shares of Danaher in the fourth quarter worth approximately $31,000. Finally, Pineridge Advisors LLC lifted its stake in shares of Danaher by 63.3% during the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate's stock worth $34,000 after acquiring an additional 57 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Shares of Danaher stock traded up $1.27 on Tuesday, reaching $197.68. 2,872,647 shares of the stock were exchanged, compared to its average volume of 3,455,650. Danaher Co. has a twelve month low of $171.00 and a twelve month high of $281.70. The business has a 50 day moving average price of $196.56 and a two-hundred day moving average price of $216.78. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $141.47 billion, a price-to-earnings ratio of 37.44, a PEG ratio of 2.66 and a beta of 0.80.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26. The business had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. Analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.65%. Danaher's dividend payout ratio is currently 24.85%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent analyst reports. Guggenheim reiterated a "buy" rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. Jefferies Financial Group decreased their price objective on shares of Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. JPMorgan Chase & Co. dropped their target price on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 22nd. Raymond James reaffirmed a "market perform" rating on shares of Danaher in a research note on Monday, February 3rd. Finally, Stifel Nicolaus raised Danaher from a "hold" rating to a "buy" rating and set a $260.00 price objective on the stock in a research note on Friday, March 14th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Danaher has a consensus rating of "Moderate Buy" and a consensus price target of $263.24.

Insider Buying and Selling at Danaher

In related news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now owns 15,179 shares in the company, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now owns 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.